Positive Results From Phase 2 Field Trial Of Travelers Diarrhea Vaccine
Travelers Diarrhea Vaccine
Iomai Corporation announces positive results from the Phase 2 field trial of the company's patch-based travelers' diarrhea vaccine.
To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at www.iomai.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network.
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea.